Natera, Inc. (NTRA)

Market Cap	21.53B
Revenue (ttm)	1.96B
Net Income (ttm)	-253.24M
Shares Out	137.25M
EPS (ttm)	-1.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	529,533
Open	159.85
Previous Close	159.81
Day's Range	155.27 - 161.38
52-Week Range	110.57 - 183.00
Beta	1.76
Analysts	Strong Buy
Price Target	194.20 (+23.82%)
Earnings Date	Aug 7, 2025

About X

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissu...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 2, 2015
• Employees: 4,434
• Stock Exchange: NASDAQ
• Ticker Symbol: NTRA
• Website: https://www.natera.com

Financial Performance

In 2024, Natera's revenue was $1.70 billion, an increase of 56.75% compared to the previous year's $1.08 billion. Losses were -$190.43 million, -56.20% less than in 2023.

Analyst Summary

According to 15 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price target is $194.2, which is an increase of 23.82% from the latest price.

Price Target

$194.2

(23.82% upside)

Analyst Consensus: Strong Buy